These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319 [Abstract] [Full Text] [Related]
3. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Shields CL, Shelil A, Cater J, Meadows AT, Shields JA. Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913 [Abstract] [Full Text] [Related]
4. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Gündüz K, Günalp I, Yalçindağ N, Unal E, Taçyildiz N, Erden E, Geyik PO. Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557 [Abstract] [Full Text] [Related]
12. Management and outcome of retinoblastoma with vitreous seeds. Manjandavida FP, Honavar SG, Reddy VA, Khanna R. Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675 [Abstract] [Full Text] [Related]
13. The International Classification of Retinoblastoma predicts chemoreduction success. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, Shields JA. Ophthalmology; 2006 Dec; 113(12):2276-80. PubMed ID: 16996605 [Abstract] [Full Text] [Related]
14. Risk Factors for Tumor Recurrence Following Primary Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma in 869 Eyes of 551 Patients. Dalvin LA, Bas Z, Tadepalli S, Rao R, Vaidya S, Pacheco R, Shields CL. J Pediatr Ophthalmol Strabismus; 2020 Jul 01; 57(4):224-234. PubMed ID: 32687206 [Abstract] [Full Text] [Related]
15. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Shields CL, Mashayekhi A, Sun H, Uysal Y, Friere J, Komarnicky L, Shields JA. Ophthalmology; 2006 Nov 01; 113(11):2087-92. PubMed ID: 16949158 [Abstract] [Full Text] [Related]
16. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Shields CL, Palamar M, Sharma P, Ramasubramanian A, Leahey A, Meadows AT, Shields JA. Arch Ophthalmol; 2009 Mar 01; 127(3):282-90. PubMed ID: 19273791 [Abstract] [Full Text] [Related]
17. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Ophthalmology; 2007 Jan 01; 114(1):162-9. PubMed ID: 17070578 [Abstract] [Full Text] [Related]
18. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Med Pediatr Oncol; 2002 Jun 01; 38(6):411-5. PubMed ID: 11984802 [Abstract] [Full Text] [Related]
19. Practical approach to management of retinoblastoma. Shields CL, Mashayekhi A, Demirci H, Meadows AT, Shields JA. Arch Ophthalmol; 2004 May 01; 122(5):729-35. PubMed ID: 15136321 [Abstract] [Full Text] [Related]
20. Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results. Rojanaporn D, Kaliki S, Bianciotto CG, Iturralde JC, Say EA, Shields CL. Arch Ophthalmol; 2012 May 01; 130(5):585-90. PubMed ID: 22652844 [Abstract] [Full Text] [Related] Page: [Next] [New Search]